drugset / Trial / NCT01989689

Etanercept and Vascular Function in Psoriasis

NCT01989689

Phase 2 Completed 24 enrolled Emory University Amgen · collab
RandomizedCrossoverTriple-blindTreatment

Summary

The investigators plan to measure the health of the vascular system of subjects taking Etanercept for the treatment of plaque psoriasis.

Timeline

Start
2010-08
Primary completion
2013-09
Completion
2013-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 50 mg Subcutaneous

Indications